New drug cocktail aims to shrink Hard-to-Treat sarcomas

NCT ID NCT04551430

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tests whether adding two immunotherapy drugs (nivolumab and ipilimumab) to the targeted therapy cabozantinib can shrink tumors better than cabozantinib alone in people with metastatic soft tissue sarcoma. About 105 adults whose cancer has worsened after prior treatments will participate. The main goal is to see how many patients have their tumors shrink or disappear.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC SOFT-TISSUE SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Abramson Cancer Center at Pennsylvania Hospital

    Philadelphia, Pennsylvania, 19106, United States

  • Stanford University Medical Center

    Stanford, California, 94305, United States

  • University of Colorado

    Aurora, Colorado, 80045, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States